Experimental stress-response small molecule · Fact sheet
ISRIB
Also known as Integrated stress response inhibitor
ISRIB is a laboratory small molecule that modulates the integrated stress response. Mouse memory and injury findings do not establish a human cognitive-enhancement or brain-injury treatment.
What is ISRIB?
The integrated stress response alters protein synthesis during cellular stress. ISRIB acts on this pathway rather than supplying a peptide or nutrient.
Related clinical-development molecules are not automatically the same compound as laboratory ISRIB.
Benefits & claims
Readers encounter ISRIB in discussions of cognition, mood or mental fatigue. The relevant study population and outcome determine whether those claims are supported.
What the evidence supports
- Mouse experiments linked stress-response inhibition to changes in memory performance.
- A traumatic-brain-injury model found reversal of selected cognitive deficits.
- These results do not prove safe long-term suppression of stress responses in people.
Research areas
- Cognition and memory
- Neurologic or psychiatric research
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for ISRIB. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- The integrated stress response alters protein synthesis during cellular stress. ISRIB acts on this pathway rather than supplying a peptide or nutrient.
Formulation differences
- Related clinical-development molecules are not automatically the same compound as laboratory ISRIB.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Reproducible benefit on everyday function in the intended population
- Long-term safety and clinically important interactions
- Equivalence of nonstandard products to research formulations
Side effects & risks
- Cellular stress responses can be protective as well as disruptive; context and timing may change consequences.
- Human pharmacokinetics, organ safety, interaction profile and repeated-exposure effects remain unestablished.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidencePrimary studies show preclinical effects on translation, neurodegeneration and mouse injury-related cognition. They do not report established human benefit.
Studies
Original ISRIB memory and translation experiments.
Preclinical neurodegeneration and protein-synthesis study.
Mouse traumatic-brain-injury cognitive study.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
ISRIB is not an FDA-approved treatment for the cognitive or mood uses discussed here. Regional use, historical trials and online availability are separate from U.S. drug approval.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
- Pharmacological brake-release of mRNA translation enhances cognitive memory.
- Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity.
- Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury.
Open questions
- Reproducible benefit on everyday function in the intended population
- Long-term safety and clinically important interactions
- Equivalence of nonstandard products to research formulations
Summary
These results do not prove safe long-term suppression of stress responses in people.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedPharmacological brake-release of mRNA translation enhances cognitive memory.
Original ISRIB memory and translation experiments.
- pubmedPartial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity.
Preclinical neurodegeneration and protein-synthesis study.
- pubmedInhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury.
Mouse traumatic-brain-injury cognitive study.